GlassScriptPhysician profile
Terry G Daniel
NPI 1578565776
$2,726.73
in general payments reported to CMS, 2019-2025
38 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $403 · 2021: $543 · 2022: $539 · 2023: $316 · 2024: $262 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $367.22 | 2019-2025 | Repatha, Otezla, Otezla |
| Supernus Pharmaceuticals, INC. | $265.69 | 2019-2022 | |
| Glaxosmithkline, LLC. | $245.50 | 2019-2024 | Shingrix |
| Lilly USA, LLC | $230.27 | 2019-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $187.08 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.09 | 2020-2024 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $136.96 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $125.13 | 2019-2024 | |
| Abbott Laboratories | $115.93 | 2019-2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $113.44 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $73.12 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $69.60 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.45 | 2020-2022 | |
| Hologic Sales and Service, LLC | $56.34 | 2023-2025 | Aptima, Acessa Provu System |
| Astrazeneca Pharmaceuticals LP | $48.28 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.